Bionano Genomics (NASDAQ: BNGO) has recently released its fourth-quarter results, indicating a positive trend of becoming more efficient while expanding its technology further into clinical applications. Despite experiencing a slight decrease in year-over-year revenue, the company's stock demonstrated resilience by surging almost 27% during Monday's trading session. In the fourth quarter, Bionano reported revenue of $8 million, surpassing its previous expectations and marking a 3% decline from the same period last year. However, the highlight was the significant increase in gross margins, which reached 46% for the full year - a substantial improvement compared to the 1% reported in 2024. This advancement was mainly attributed to a strategic shift towards generating recurring revenue streams. For further details, please refer to the complete article on Benzinga.com.